30 products | 23 new records + 7 supplemented records
Renal findings at a glance
Start with the action, then check the limitation. Each panel is tied to one identified primary source, not a merged recommendation. Open the full quick answer for tables, exact product scope, units, dates, RX evidence and existing source differences.
No patient dose is calculated. Selected renal passages are not complete monographs or independent clinical approval. No-adjustment guidance does not eliminate monitoring; PK findings do not establish a dialysis regimen.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
This source only - not a merged recommendation
What matters first
Product: Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal action / finding
Label: no renal adjustment required.
Evidence or dialysis limit
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Monitoring / application
Subcutaneous infusion only; use the labeled weight-based regimen.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source revision: Revision date not captured in selected review; retrieval date is not revision date. Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
This source only - not a merged recommendation
What matters first
Product: Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.
Renal action / finding
No renal dose adjustment recommended.
Evidence or dialysis limit
Kidney-failure PK evidence is not a modality-specific dialysis schedule.
Monitoring / application
Monitor kidney function with volume-depleting reactions, especially during initiation/escalation.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: Qualitative renal categories including kidney failure; no new renal threshold
Source revision: Revision date not captured in selected review; retrieval date is not revision date. Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
This source only - not a merged recommendation
What matters first
Product: Adult TALVEY subcutaneous therapy for its labeled myeloma setting; not a complete treatment or step-up regimen.
Renal action / finding
Mild/moderate PK finding, not a derived renal dose.
Evidence or dialysis limit
CrCl <30 effects unknown; no dialysis regimen established.
Monitoring / application
Retain the exact product step-up and safety monitoring requirements.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: Cockcroft-Gault CrCl, mL/min
Source revision: Revision date not captured in selected review; retrieval date is not revision date. Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
This source only - not a merged recommendation
What matters first
Product: Adult TECVAYLI subcutaneous therapy for its labeled myeloma setting; not a complete treatment or step-up regimen.
Renal action / finding
Mild/moderate PK finding, not a derived renal dose.
Evidence or dialysis limit
eGFR <30 effects unknown; no dialysis regimen established.
Monitoring / application
Retain the exact product step-up and safety monitoring requirements.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: MDRD eGFR, mL/min as printed in the primary label
Source revision: Revision date not captured in selected review; retrieval date is not revision date. Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
This source only - not a merged recommendation
What matters first
Product: Adult ZEPBOUND subcutaneous product for its labeled indications; confirm brand, device and escalation schedule rather than substituting another tirzepatide regimen.
Renal action / finding
No renal dose adjustment recommended.
Evidence or dialysis limit
ESRD PK finding does not supply a modality-specific dialysis schedule.
Monitoring / application
Monitor renal function with volume depletion; verify device and titration.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: Qualitative renal categories including ESRD in PK study
Source revision: 08/2026 Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
This source only - not a merged recommendation
What matters first
Product: OJEMDA for labeled BRAF-altered relapsed/refractory pediatric low-grade glioma, age >=6 months; preserve age-appropriate renal estimation and formulation.
Renal action / finding
eGFR >=30 mL/min/1.73 m2: no renal adjustment.
Evidence or dialysis limit
eGFR <30 not studied; no dialysis regimen established.
Monitoring / application
Use age-appropriate Schwartz/MDRD interpretation and the labeled oncology regimen.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Renal measure: Indexed eGFR, mL/min/1.73 m2, calculated by Schwartz or MDRD as stated in the label
Source revision: Revision date not captured in selected review; retrieval date is not revision date. Selected sections checked: 2026-11-07. Revision and retrieval dates are different.
Thirty previously uncovered RX URLs now have selected summaries; five other attempted pages did not yield usable renal text. All 26 A-Z letters still require complete linked-monograph review. The separate historical drug archive was not used.
